RevBio Secures 10th Patent for TETRANITE®: Expanding Protection for Revolutionary Bone Adhesive Technology
In a significant milestone for regenerative medicine, ITS, a clinical-stage medical device company, has been granted its 10th U.S. patent for its groundbreaking TETRANITE® bone adhesive technology. The United States Patent and Trademark Office (USPTO) recently issued patent 12,178,937, titled “Compositions and Methods for Adhesion to Surfaces,” which broadens the scope of RevBio’s intellectual property portfolio. This latest patent extends protection to include injectable mineral-organic structural bone adhesive compositions containing alpha tricalcium phosphate, further solidifying RevBio’s leadership in the field of advanced biomaterials.
The issuance of this patent complements It’s existing patent 11,638,777, which covers methods for repairing fractured bones using the same adhesive composition. Together, these patents significantly enhance the company’s ability to develop and market innovative solutions for bone repair, addressing unmet needs in orthopedics, dentistry, and beyond.
A Breakthrough in Bone Regeneration
At the heart of RevBio’s innovation is TETRANITE®, a patented synthetic biomaterial that represents a paradigm shift in bone repair. Unlike traditional approaches, TETRANITE® combines excellent handling characteristics, weight-bearing strength, and high biocompatibility with unique adhesive and bone-regenerative properties. What sets this biomaterial apart is its inclusion of phosphoserine, an organic compound shown in published studies to play a critical role in bone regeneration. This distinctive feature makes TETRANITE® the only patented bone adhesive technology to incorporate phosphoserine, offering unparalleled potential for healing fractures and improving patient outcomes.
“The granting of this patent continues to expand RevBio’s controlling intellectual property estate in the mineral-organic bone adhesive space,” said George Kay, DMD, Chief Scientific Officer and co-founder of RevBio. “This novel and highly promising biomaterial uniquely combines excellent handling, weight-bearing strength, and high biocompatibility with remarkable adhesive and bone regenerative properties.”
Strengthening Intellectual Property and Market Potential
RevBio’s robust intellectual property strategy underscores its commitment to protecting and advancing its innovative platform. In addition to the newly issued patent, the company holds an exclusive worldwide license from Stryker Corporation (NYSE: SYK) for six patent families covering TETRANITE®’s composition and specific methods of use. These patents provide protection through 2033, ensuring a lengthy period for RevBio to develop and commercialize its products.
Since 2016, RevBio has filed 14 Patent Cooperation Treaty (PCT) applications, expanding its global reach and securing long-term protection for its technology. Several of these applications have already been granted as U.S. patents, while others are in various stages of prosecution in key markets such as the United States, European Union countries, Canada, Australia, Japan, and China. Collectively, these patents safeguard not only the original TETRANITE® formulation but also derivatives, expanded methods of use, ancillary devices, and packaging innovations. Many of these protections extend through 2043, positioning RevBio as a dominant player in the regenerative medicine space.
Transformative Applications Across Multiple Markets
RevBio’s TETRANITE® technology is designed to address a wide range of clinical challenges, particularly in areas where traditional treatments fall short. Initially, the company is focusing on applications in:
- Dental Surgery: Enhancing stability and promoting faster healing in dental implants and bone grafts.
- Cranial Procedures: Providing precise adhesion and structural support in cranial repairs.
- Orthopedic Care: Offering innovative solutions for fracture repair and joint stabilization.
- Animal Health: Extending the benefits of TETRANITE® to veterinary applications, addressing similar needs in animal patients.
The versatility of TETRANITE® positions it as a game-changing solution across multiple markets, with the potential to revolutionize how fractures and bone defects are treated. As a synthetic, injectable, self-setting, and osteoconductive biomaterial, TETRANITE® eliminates many limitations associated with conventional bone cements and adhesives, such as poor biocompatibility and inadequate bonding strength.
Strategic Growth and Investor Confidence
For RevBio, the issuance of this latest patent reinforces the company’s value proposition and strengthens its competitive edge. According to Brian Hess, CEO and founder of RevBio, “As a clinical-stage company, it is exciting to receive this key patent that expands patent protection for the full spectrum of indications we are pursuing. This new patent will enhance the company’s core value and competitive advantage for our investors who are funding the development of this game-changing technology platform.”
With a growing portfolio of patents and a clear path to commercialization, RevBio is well-positioned to attract additional investment and partnerships. The company’s focus on developing cutting-edge solutions for unmet medical needs aligns perfectly with the demands of modern healthcare, making TETRANITE® a highly attractive prospect for stakeholders across the industry.
About RevBio, Inc.
Founded with a mission to transform bone repair and regeneration, RevBio, Inc. is a clinical-stage medical device company at the forefront of biomaterial innovation. Its flagship product, TETRANITE®, is a patented synthetic bone adhesive designed to provide superior adhesion, strength, and biocompatibility while promoting natural bone regeneration. Although TETRANITE® is not yet approved for commercial use, RevBio is actively advancing its development for applications in dentistry, orthopedics, cranial surgery, and animal health.
By leveraging its extensive intellectual property portfolio and commitment to scientific excellence, RevBio aims to redefine the standard of care in bone repair. With a vision to improve patient outcomes and reduce recovery times, the company is paving the way for a future where fractures and bone defects can be addressed more effectively and efficiently than ever before.
For more information about RevBio and its transformative TETRANITE® technology, visit www.revbio.com.
